Without the permission of our company, Shanghu.com has unauthorizedly used the relevant information of Sichuan Jiuzhang Biotechnology Co., Ltd. (including the company's introduction, contact information, address, product information, etc.) to carry out the sales promotion of chlorogenic acid bulk drugs. After our company discovered and verified this situation, we immediately notified Shanghu.com to delete the relevant information. However, up to now, Shanghu.com has still not deleted the relevant information. In order to prevent our numerous customers and relevant cooperative units of Jiuzhang Biology from suffering economic losses due to this, we hereby issue this information announcement. Our company will continue to negotiate with Shanghu.com to safeguard our legitimate rights and interests.

On December 10, 2014, Sichuan Jiuzhang Biotechnology Co., Ltd. and the Institute of Materia Medica, Chinese Academy of Medical Sciences jointly initiated the establishment of the CHA Research and Development Cooperative Committee. Based on the potentially huge scientific value of CHA in scientific and technological and clinical application aspects, the committee will, from a comprehensive perspective, plan and guide the research direction of the CHA project, standardize and supervise the information dissemination and information security during the research and development process of CHA. By gathering innovative elements, activating innovative resources, transforming innovative achievements, etc., it aims to achieve the sustainable development of CHA-related research.

On December 10, 2014, the "Research and Development Seminar on CHA Injection, a Class 1.2 Antitumor New Drug" was organized by the Institute of Materia Medica, Chinese Academy of Medical Sciences and held in Beijing. The participating experts and leaders are as follows:

The "Phase 1 Clinical Trial on the Tolerance and Pharmacokinetic Characteristics of CHA for Injection in Subjects with Advanced Cancer" was approved by the Medical Ethics Committee of Beijing Cancer Hospital on September 3, 2014.

In August 2013, CHA and CHA for injection obtained the clinical trial approval documents from the China Food and Drug Administration (CFDA).

Our company assembled its technical backbones, gave full play to its scientific research advantages, and after long-term research, with the strenuous efforts of the scientific research team led by Wang Li, Yang Huarong, and Wang Zhu, a scientific and detailed experiment on the sensitization of CHA was carried out. And a paper titled "Comprehensive Evaluation of the Non-sensitizing Property of CHA" was published in the authoritative journal "Chinese Journal of Medicinal Guide", which aroused a strong response from relevant people. It opened up new ideas and windows for the treatment and control of cancer and brought good news to cancer patients.